Navigation Links
Neuraltus Pharmaceuticals Awarded $733,437 Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
Date:11/5/2010

PALO ALTO, Calif., Nov. 5, 2010 /PRNewswire/ -- Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases, announced today the Company was awarded three grants totaling $733,437 under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP).  The grants are being provided under section 48D of the Internal Revenue Code, enacted as part of the Patient Protection and Affordable Care Act of 2010.  The grants will be used to advance Neuraltus' product pipeline, including NP001, NP002 and NP003.  

Neuraltus currently is evaluating NP001 for the treatment of Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease) in an ongoing Phase 1 study. NP001 is a novel small molecule that regulates macrophage activation, with potential application to a number of neurodegenerative diseases, including ALS, Alzheimer's disease, Parkinson's disease and multiple sclerosis.  NP002, Neuraltus' small molecule, nicotinic receptor agonist currently is in a Phase 1/2 study for L-dopa-induced dyskinesias (muscle movement disorders), a primary side effect of L-dopa treatment in Parkinson's disease patients.  In addition, Neuraltus is developing NP003, an orally bioavailable, small molecule designed to treat lysosomal storage disorders such as Fabry's disease and Gaucher's disease, as well as Parkinson's disease.

Andrew Gengos, Neuraltus' President and CEO, commented, "We are very pleased to receive this grant.  There remain significant unmet needs in the treatment of neurodegenerative diseases, specifically, ALS, Alzheimer's disease and Parkinson's disease.  Each of Neuraltus' programs represents a first-in-class approach to treating these indications.  With the help of the QTDP grant, Neuraltus will be able to further develop NP001, NP002 and NP003
'/>"/>

SOURCE Neuraltus Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2, 2015 Demers Ambulances is proud to announce ... new dealer for the states of Mississippi ... . "This will enable Demers to ... Lafortune , Executive Vice-President for Demers Ambulances. "Emergency Equipment Professionals ... and Alabama , giving them a ...
(Date:9/2/2015)... BOCA RATON, Fla. , Sept. 2, 2015 ... Cartledge , MD, FACS, has begun performing ultra-minimally ... patients who are on anticoagulants such as Coumadin, ... of Cardiothoracic Surgery at the Hospital, is one ... this method, which involves making two microscopic incisions ...
(Date:9/2/2015)... -- Aethlon Medical, Inc. (Nasdaq: AEMD ), today announced that ... at the Rodman & Renshaw 17th Annual Global Investment Conference ... a.m. ET on Thursday, September 10, 2015. The ... audio webcast which can be accessed by visiting the investor ... . The webcast will be archived for thirty days.  ...
Breaking Medicine Technology:Demers Ambulances has named Emergency Equipment Professionals (EEP) Inc. as their dealer for the states of MS, AL and TN 2Boca Regional Introduces Ultra-Minimally Invasive Surgical Procedure for Atrial Fibrillation Patients 2Boca Regional Introduces Ultra-Minimally Invasive Surgical Procedure for Atrial Fibrillation Patients 3
... Texas, March 15, 2011 Argon Medical Devices, Inc. ... license agreement with Rex Medical, LP ("Rex Medical") for exclusive ... Vena Cava Filter, an implantable device used in the prevention ... with the addition of Option™ to our product portfolio. This ...
... March 15, 2011 OncoSec Medical Inc. (OTC Bulletin ... and proprietary medical approaches to treat solid tumor cancers ... signed an agreement with Inovio Pharmaceuticals, Inc. (NYSE Amex: ... OncoSec of certain non-DNA vaccine technology and intellectual property ...
Cached Medicine Technology:Argon Medical Devices Announces Exclusive License and Distribution Agreement for Option™ Retrievable Inferior Vena Cava Filter 2Argon Medical Devices Announces Exclusive License and Distribution Agreement for Option™ Retrievable Inferior Vena Cava Filter 3OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals 2OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals 3OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals 4
(Date:9/2/2015)... ... September 02, 2015 , ... Alameda County Community Food ... Action Month” during the entire month of September. In the spirit of ... its efforts this September to an awareness campaign educating legislators and the public ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... Cancer Center at Children's Healthcare of Atlanta to help support childhood cancer ... discuss the upcoming WSB Radio Care-A-Thon , which is the fund-raising event ...
(Date:9/2/2015)... ... September 02, 2015 , ... Medical ... has completed a recapitalization with new investment partners Beecken Petty O’Keefe & ... each offer extensive expertise and connections within the healthcare industry, which makes ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... Every year ... it; others dread it. However, few are prepared to face the academic workload confronting ... starts. Our schools haven’t prepared them since schools don’t teach students how to study. ...
(Date:9/2/2015)... Destin, Florida (PRWEB) , ... September 02, 2015 , ... ... in drug prices over the past year and its negative impact on consumers. It ... regular prescription medication and 10% were paying as much as an extra $100 compared ...
Breaking Medicine News(10 mins):Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 2Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 3Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 4Health News:DoMyOwnPestControl.com Goes Gold for Childhood Cancer Awareness Month 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 3Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 4Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 2Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 3Health News:Watertree Health President Responds to Consumer Reports Survey on Rising Prescription Drug Prices 2
... says hazard isn,t proven, , SATURDAY, Sept. 5 (HealthDay ... (pronounced THAL ates) are nearly ubiquitous in consumer products, ... plastics and toys. , A little over a decade ... began to focus on phthalates and have been working ...
... , ST. LOUIS, Sept, 4 KV ... Thomas McHugh, the Vice President of Finance and Corporate Controller of ... Mr. McHugh replaces Ronald J. Kanterman, who ceased serving as ... Mr. Kanterman continues to serve as a member of the ...
... NEWPORT BEACH, Calif., Sept. 4 Nationwide Health Properties ... Portfolio Officer, Abdo Khoury, will participate on a healthcare real estate ... Conference on Friday, September 11, 2009 beginning at 7:30 a.m. CDT. ... a live audio-webcast, please us the following link: ...
... University of Toronto have identified a protein which plays ... could enhance our understanding of how the brain works, ... of T graduate student John Calarco, working in the ... and Biomolecular Research, University of Toronto) and Prof. Mei ...
... major episode later, researchers say , FRIDAY, Sept. 4 ... to have major depression, anxiety disorders and eating disorders ... researchers interviewed 755 teenagers who were about age 16 ... substance abuse. , About 8 percent were found to ...
... ... ... American Pharmacists Association (APhA) is recommending that the public begin visiting their ... 80,000 pharmacists have been trained to administer immunizations and have the authority to administer ...
Cached Medicine News:Health News:In Toys and More, Are Chemicals Safe or Harmful? 2Health News:In Toys and More, Are Chemicals Safe or Harmful? 3Health News:KV Pharmaceutical Appoints Interim Chief Financial Officer 2Health News:KV Pharmaceutical Appoints Interim Chief Financial Officer 3Health News:KV Pharmaceutical Appoints Interim Chief Financial Officer 4Health News:KV Pharmaceutical Appoints Interim Chief Financial Officer 5Health News:KV Pharmaceutical Appoints Interim Chief Financial Officer 6Health News:U of T researchers identify protein 2Health News:Depressed Teens Continue to Suffer 2Health News:Pharmacists Urge the Public to Begin Getting Immunized 2Health News:Pharmacists Urge the Public to Begin Getting Immunized 3
... System RCS 800 closes various plastic primary and ... way. Different tube heights and diameters can be ... be used for send-outs. The integration into other ... System RSD 800 and High Throughput Sorter RSD ...
... Decapping System DS 800 selectively removes closures from ... the barcode towards the rack opening in one ... integrated in PVT Systems like Sorting System RS ... Sorter RSD ProVolume and Aliquoting System RSD 800A. ...
... Nanogen offers reagents to detect ... human parainfluenza virus 1, 2 and ... and respiratory syncytial virus A and ... reagents to create homebrew tests., ...
... Alert Detection Reagents provide molecular labs a ... assays. By using our MGB technology, combined ... is now able to provide molecular labs ... sequences of specific organisms or genetic mutations ...
Medicine Products: